title: [Effectiveness and tolerability of celecoxib in outpatient department practice].
abstract: OBJECTIVE
  Object of this work is to evaluate activity and tolerance of Celecoxib in out-patient's department practice.
  
  
  METHODS
  In this study we enlisted 46 patients, affected by pain of inflammatory or degenerative origin; any of them ever did continued therapy with NSAIDs before. We administered 200 mg daily dose of Celecoxib for at least three months. Each patient has been evaluated by the Visual Analogic Score (VAS) Scale before and after the therapy.
  
  
  RESULTS
  The data We obtained agree with those of multicenter studies like CLASS. Celecoxib had similar efficacy respect with traditional NSAIDs, with good control of pain in both osteoarthrosic and arthritic pain (p < 0.000). Not good results were obtained for control of acute-onset pain. In our population We didn't find side-effects different from those included in the technical-form of the drug. The only patient who complained of epigastric pain did not stop the treatment, because the symptom resolved with assumption of the drug during meals.
  
  
  CONCLUSIONS
  By the analysis of the results We consider Celecoxib useful for the control of pain in the treatment of osteoarthrosis and autoimmune diseases like Rheumatoid Arthritis. Anyway, treatment with Celecoxib (as with all Coxib-family drugs) should be reserved for long-lasting treatments in patients at risk for gastrointestinal bleeding.
authors.affiliation: Università Campus Bio-Medico, Area di Ortopedia e Traumatologia, Roma, Italia. F.Cancilleri@unicampus.it
authors.forename: F
authors.initials: F
authors.lastname: Cancilleri
authors.forename: G
authors.initials: G
authors.lastname: Caione
authors.forename: A
authors.initials: A
authors.lastname: Di Martino
authors.forename: A
authors.initials: A
authors.lastname: Marinozzi
authors.forename: G M F
authors.initials: GM
authors.lastname: Stellato
authors.forename: V
authors.initials: V
authors.lastname: Denaro
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068579:Celecoxib; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy; D010045:Outpatients; D010147:Pain Measurement; D011720:Pyrazoles; D018709:Statistics, Nonparametric; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib